L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial

Araminia, Behin; Shalbafan, Mohammadreza; Mortezaei, Amirhosein; Shirazi, Elham; Ghaffari, Salomeh; Sahebolzamani, Erfan; Mortazavi, Seyyed Hosein; Shariati, Behnam; Ardebili, Mehrdad Eftekhar; Aqamolaei, Ali; Naderi, Sina; Akhondzadeh, Shahin

doi:10.1016/j.jad.2020.02.020

Cited by 21 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent clinical neuroscience endeavors include clinical trials with novel medications (Araminia et al, 2020; Shalbafan, Malekpour, et al, 2019), neurocognitive and neuroimaging assessments in psychiatric patients (Bagherzadeh‐Azbari et al, 2019), and neuro‐stimulation modalities amongst psychiatric patients, and have yielded numerous publications in international journals.…”

Section: Methodsmentioning

confidence: 99%

The state of psychiatric research in the Asia Pacific region

Roche

Fung

Ransing

et al. 2020

Asia-Pacific Psychiatry

Self Cite

View full text Add to dashboard Cite

Introduction This study aims to review recent scientific publications and research output in the field of psychiatry, from a series of countries in the Asia‐Pacific region (Australia, India, Indonesia, Iran, Lebanon, Malaysia, and Nepal), with a view to identify themes and similarities across regions, as well as to examine the barriers and challenges in mental health research faced by countries in the region. Methods Seven psychiatrists from seven countries reviewed recent published and ongoing research in psychiatry in their respective nations, with respect to themes, as well as any barriers or challenges faced by mental health researchers. Results While the seven nations included in this review vary in terms of research capabilities and economic development level, they share many similarities both in terms of research direction, and with regards to challenges faced. Limitations in the form of sociocultural differences from the West, and a lack of funding were some of the barriers identified. Discussion Mental health research in the region has been progressing well. However, more varied research in the form of qualitative or economic studies are lacking, as are multi‐center studies. The similar issues that nations face with regards to research could perhaps benefit from collaborative efforts and initiatives for the furtherance of research in the region.

show abstract

Section: Methodsmentioning

confidence: 99%

The state of psychiatric research in the Asia Pacific region

Roche

Fung

Ransing

et al. 2020

Asia-Pacific Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…L-carnosine is a nutritional complementary agent with both antioxidant and glutamatergic properties. Carnosine reduces the glutamate levels in the central nervous system via upregulation of the glutamate transporter 1 [ 28 – 30 ]. One of the studies assessed the effect of L-carnosine as adjunct therapy to fluvoxamine in OCD and found significant decrease in final Y-BOCS score (t42:-2.62, P -value:< 0.001) [ 31 ].…”

Section: Resultsmentioning

confidence: 99%

Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis

Hadi

Kashefinejad

Kamalzadeh

et al. 2021

BMC Pharmacol Toxicol

Self Cite

View full text Add to dashboard Cite

Background Obsessive-compulsive disorder (OCD) is among the most disabling neuropsychiatric conditions characterized by the presence of repetitive intrusive thoughts, impulses, or images (obsessions) and/or ritualized mental or physical acts (compulsions). Serotonergic medications, particularly Selective Serotonin Reuptake Inhibitors (SSRIs), are the first-line treatments for patients with OCD. Recently, dysregulation of glutamatergic system has been proposed to be involved in the etiology of OCD. We designed this systematic review and meta-analysis to evaluate clinical efficacy of glutamatergic medications in patients with OCD, according to the guidelines of Cochrane collaboration. Method We searched Medline, Scopus, and Cochrane library without applying any language filter. Two of the authors independently reviewed search results for irrelevant and duplicate studies and extracted data and assessed methodological quality of the studies. We transformed data into a common rubric and calculated a weighted treatment effect across studies using Review Manager. Results We found 476 references in 3 databases, and after exclusion of irrelevant and duplicate studies, 17 studies with total number of 759 patients with OCD were included. In the present review we found evidence for several drugs such as memantine, N-acetylcysteine (NAC), Minocycline, L-carnosine and riluzole. Glutamaterigic drug plus SSRIs were superior to SSRI+ Placebo with regard to Y-BOCS scale [standardized mean difference (SMD = − 3.81 95% CI = − 4.4, − 3.23). Conclusion Augmentation of glutamatergic medications with SSRIs are beneficial in obsessive-compulsive patients, no harmful significant differences in any safety outcome were found between the groups.

show abstract

“…They have also reported the rapid-onset antidepressant effect of carnosine, which requires researchers' attention in further studies. 52 Theanine Theanine or L-theanine is an alpha-amino acid found naturally in green tea (Camellia sinensis), black tea, and some fungi. 53,54 L-Theanine, like caffeine and catechin, is responsible for an essential part of the health effects of tea.…”

Section: Carnosinementioning

confidence: 99%

Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence

Shamabadi

Akhondzadeh

2021

Arch Iran Med

Self Cite

View full text Add to dashboard Cite

Depression is a chronic and debilitating psychiatric disorder that affects 300 million people worldwide. Pharmacotherapy is one of the treatments. Due to delay in initiating treatment efficacy and the incomplete response to mono-drug therapy in onethird of patients, new approaches need to be considered. One of the ways to overcome this resistance to treatment and to enhance standard medical practice is to add complementary medicines. We aimed to document research progress from studies on integrative medicine for the treatment of depression. Review of PubMed and Scopus databases on the topic and a personal collection of the relevant publications are the sources for this study. Some of the nutraceuticals and complementary medicines in the treatment of depression will be reviewed. Supplements discussed in this review include S-adenosyl-methionine (SAMe), Crocus sativus (Saffron), carnosine, theanine, palmitoylethanolamide (PEA), tryptophan and 5-hydroxytryptophan (5-HTP), gemfibrozil, curcumin (the main active ingredient in turmeric), Hypericum perforatum (St John's wort), Lavandula angustifolia (Lavender), and Cinnamomum tamala. Despite evidence in favor of the antidepressant effect of several supplements, their efficacy and tolerability should be evaluated and validated by further high-quality studies.

show abstract

L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial

Cited by 21 publications

References 41 publications

The state of psychiatric research in the Asia Pacific region

The state of psychiatric research in the Asia Pacific region

Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis

Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence

Contact Info

Product

Resources

About